← All companies
TOI
The Oncology Institute, Inc.
$5.13
+0.06 +1.18%
Key statistics
from XBRL data in SEC filingsMarket cap
$513M
Revenue (TTM)
$546M
Net income (TTM)
$60.6B
EPS (TTM)
$-0.35
P/E ratio
—
Dividend yield
—
Free cash flow
-$27.8M
Cash
$30.3M
Total assets
$168M
Gross margin
—
52-week range
$2.32 – $6.67
Recent SEC filings
40 most recentAnnual, quarterly & current reports
8-K
Amended charter or bylaws; Regulation FD disclosure
Aug 3, 2026
8-K
Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity; Regulation FD disclosure
Jul 7, 2026
8-K
Shareholder vote results
Jun 18, 2026
8-K
Item 1.05
May 22, 2026
8-K
Results of operations (earnings release)
May 7, 2026
10-Q
Quarter ended 2026-03-31
May 7, 2026
8-K
Regulation FD disclosure
Mar 13, 2026
10-K
Fiscal year ended 2025-12-31
Mar 12, 2026
8-K
Results of operations (earnings release)
Mar 12, 2026
8-K
Director or officer change; Regulation FD disclosure
Feb 23, 2026
8-K
Results of operations (earnings release)
Jan 12, 2026
8-K
Director or officer change; Regulation FD disclosure
Jan 7, 2026
8-K
Director or officer change; Regulation FD disclosure
Dec 1, 2025
8-K
Regulation FD disclosure
Nov 14, 2025
10-Q
Quarter ended 2025-09-30
Nov 13, 2025
8-K
Results of operations (earnings release)
Nov 13, 2025
8-K
Regulation FD disclosure
Nov 6, 2025
10-Q
Quarter ended 2025-06-30
Aug 13, 2025
8-K
Results of operations (earnings release)
Aug 13, 2025
8-K
Director or officer change; Regulation FD disclosure
Aug 13, 2025
8-K
Regulation FD disclosure
May 19, 2025
8-K
Results of operations (earnings release)
May 14, 2025
10-Q
Quarter ended 2025-03-31
May 14, 2025
8-K
Shareholder vote results
May 8, 2025
8-K
Director or officer change
May 7, 2025
8-K
Other events
Apr 11, 2025
8-K
Entered a material agreement; Unregistered sale of equity
Mar 27, 2025
10-K
Fiscal year ended 2024-12-31
Mar 26, 2025
8-K
Entered a material agreement; Unregistered sale of equity; Modified rights of security holders; Amended charter or bylaws; Regulation FD disclosure
Mar 25, 2025
8-K
Regulation FD disclosure
Mar 24, 2025
8-K
Results of operations (earnings release)
Mar 24, 2025
8-K
Entered a material agreement; Regulation FD disclosure
Feb 26, 2025
8-K
Delisting notice or listing-rule failure
Dec 19, 2024
10-Q
Quarter ended 2024-09-30
Nov 13, 2024
8-K
Results of operations (earnings release)
Nov 13, 2024
8-K
Director or officer change
Nov 12, 2024
8-K
Director or officer change; Regulation FD disclosure
Sep 23, 2024
10-Q
Quarter ended 2024-06-30
Aug 13, 2024
8-K
Results of operations (earnings release)
Aug 13, 2024
8-K
Delisting notice or listing-rule failure
Jun 21, 2024